Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (unaudited)

v2.4.0.6
Condensed Consolidated Statements of Cash Flows (unaudited) (USD $)
In Thousands, unless otherwise specified
 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Cash flows from operating activities:    
Net loss $ (28,500) $ (19,686)
(Income) loss from discontinued operations, net of tax (183) 2,841
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 7,447 2,858
Accretion of debt discount related to notes payable   2
Equity-based compensation - employees and non-employees 3,281 5,350
Loss from investments in investees 1,464 1,175
Provision for bad debt 11 260
Provision for inventory obsolescence 1,520 534
Revenue from receipt of equity in Neovasc (159)  
Unrealized gains on derivative investments (1,309)  
Changes in fair value of contingent consideration 2,665  
Changes in assets and liabilities of continuing operations, net of the effects of acquisitions:    
Accounts receivable (184) (2,523)
Inventory (4,443) 4,080
Prepaid expenses and other current assets (1,312) 224
Other assets 77 53
Accounts payable (331) (3,652)
Foreign currency measurement (204)  
Accrued expenses 459 852
Cash used in operating activities of continuing operations (19,701) (7,632)
Cash provided by (used in) operating activities of discontinued operations 14 (4,280)
Net cash used in operating activities (19,687) (11,912)
Cash flows from investing activities:    
Acquisition of businesses, net of cash (10,512) (10,538)
Purchase of marketable securities (28,923) (100,161)
Maturities of short-term marketable securities 10,000 59,982
Investments in investees (2,700) (2,013)
Capital expenditures (1,064) (1,249)
Net cash used in investing activities (33,199) (53,979)
Cash flows from financing activities:    
Issuance of Common Stock, including related parties, net   104,828
Purchase of common stock held in treasury   (7,832)
Redemption of Series A Preferred Stock   (1,792)
Borrowings under lines of credit 29,389 10,056
Repayments under lines of credit (26,108) (10,761)
Proceeds from the exercise of Common Stock options and warrants 1,702 774
Net cash provided by financing activities 4,983 95,273
Effect of exchange rate changes on cash and cash equivalents (185) (163)
Net (decrease) increase in cash and cash equivalents (48,088) 29,219
Cash and cash equivalents at beginning period 71,516 18,016
Cash and cash equivalents at end of period 23,428 47,235
SUPPLEMENTAL INFORMATION    
Interest paid 613 608
Income taxes paid 515 355
Non-cash financing activities:    
Issuance of Common Stock to acquire Farmadiet 805  
Common Stock warrants, net exercised $ 7 $ 1,155